Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01446250 · ClinicalTrials.gov registry record · Phase 3
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
A Phase 3 study, sponsored by Debiopharm International.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT01446250: Clinical Trial Phase 3 study, sponsored by Debiopharm International.
NCT01446250 is a Phase 3 study that was terminated before completion, run by Debiopharm International. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01446250, a Phase 3 study, was terminated before completion, sponsored by Debiopharm International.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received treatment for their chronic hepatitis C (HCV) genotype 1 infection.
Interventions
- DRUG Ribavirin
- DRUG Peginterferon alfa-2a
- DRUG Alisporivir
- DRUG Boceprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Why NCT01446250 stopped before completion
NCT01446250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01446250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01446250 about?
NCT01446250 is a clinical study titled "Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1". This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received treatment for their chronic hepatitis C (HCV) genotype 1 infection.
What is the current status of trial NCT01446250?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2011-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01446250?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a (DRUG), Alisporivir (DRUG), Boceprevir (DRUG).
Who is sponsoring clinical trial NCT01446250?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01446250's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia